I did not say IPIX cannot apply for EUA after Phase 2. What I meant was what advantage does IPIX have over Pfizer to bypass Phase 3. Is it based on data of the 60 patients who received B (possibly without statistical significance), or is it because IPIX is a penny stock and not in the FDA's pocket?